Rupture of the lumbar artery is usually associated with trauma but rarely has been reported in association with anticoagulation. We present a 71-year-old man who developed spontaneous rupture of the lumbar artery leading to a retroperitoneal hematoma while receiving continuous renal replacement therapy (CRRT). The bleeding was confirmed by computed tomography and angiography and was controlled successfully using selective angiographic embolization. We suggest that spontaneous retroperitoneal bleeding should be considered in a case of sudden decrease in hemoglobin in a CRRT patient.
increased intima-media thickness in the common carotid artery.
We administered intravenous furosemide, but edema and pleural effusion worsened (Fig. 1) . On day 5 after admission, the patient was transferred to the intensive care unit (ICU) and CRRT was performed. The treatment settings were blood flow, 120 mL/min; dialysate flow, 1,000 mL/h; replacement fluid flow, 1,000 mL/h; and ultrafiltration rate, 200-300 mL/h. Heparin was administered as a bolus of 2,000 international units (IU), followed by continuous infusion of 600 IU/h into the dialysis circuit.
On day 8 after admission, the 3rd day of CRRT, the patient exhibited a change in mental status. His blood pressure was 60/40 mmHg and pulse rate was 114 beats/min. Hemoglobin fell to 4.4 g/dL. PT and PTT were within normal range (13 sec/32.4 sec) and his platelet count was 147,000/mm 3 . Under suspicion of internal bleeding and hemorrhagic shock, we administered intravenous fluids, blood transfusion, and oxygen supplementation; we also injected erythropoietin.
The patient underwent abdominal computed tomography, which showed a large hematoma in the right retroperitoneum and the right iliacus muscle (Fig. 2) . For diagnostic and therapeutic purposes, the patient underwent emergent CRRT is an extracorporeal blood purification therapy intended to substitute for impaired renal function over an extended period of time; it is administered 24 hours a day.
[9] The use of CRRT in critically ill patients with acute renal failure, combined with cardiovascular instability, severe fluid overload, cerebral edema or hypercatabolism and high fluid requirements, is widely accepted. It can also be used in patients in refractory chronic edematous states or with pulmonary edema. [10] One requirement of CRRT that has potential deleterious consequences is anticoagulation. While anticoagulation exposes patients to the risk of bleeding, the absence of it may result in clotting of the CRRT circuit. Bleeding during anticoagulation for CRRT is reported in 5-25% of patients, [11] [12] [13] although the incidence depends on the population and the criteria used to define bleeding. Optimal anticoagulation methods are easy to implement and monitor, have few side effects, and are cost effective.
Common treatment options include unfractionated heparin, regional citrate, no anticoagulation, and thrombin antagonists. Less commonly used modalities include heparin with protamine reversal, low-molecular-weight heparins, heparinoids, and platelet-inhibiting agents.
Unfractionated heparin (UFH) remains the most widely used anticoagulant for CRRT. The risk of hemorrhage is the main drawback to UFH. The reported incidence of bleeding ranges from 10-50%, with mortality due to bleeding as high as 15%. [14] [15] [16] It has been suggested that the risk of hemorrhage or clotting of the extracorporeal circuit is a function of aPTT rather than heparin dose. [14] Regional citrate can be used for patients who are at high risk for bleeding. When citrate is used, metabolic monitoring is necessary and the composition of the CRRT fluids must be adjusted. Meta-analysis revealed longer circuit survival and less bleeding with the use of citrate compared with UFH. [17] However, citrate is now being replaced by other anticoagulants in Korea, because citrate anticoagulation is Nafamostat mesilate is now used widely in patients who are at high risk for bleeding.
As CRRT is increasingly used in the critical care/ICU setting, the need for anticoagulation presents greater challenges because many critically ill patients with sepsis and inflammation are already at higher risk of bleeding as well as clotting.
In conclusion, we suggest that the possibility of spontaneous retroperitoneal bleeding should be considered in CRRT patients with sudden decreases in hemoglobin. Anticoagulant selection for CRRT should be determined based on patient characteristics, local expertise, nursing comfort and ease of monitoring.
